Foghorn presents preclinical data at AACR: FHD-909 combo shows complete regression and immune memory

Foghorn Therapeutics Inc.

FHD-909 (SMARCA2 inhibitor) plus anti-PD-1 achieved complete tumor regression and immune memory in preclinical SMARCA4-mutant models.
Selective CBP degrader FHT-171 showed strong anti-tumor activity and favorable tolerability in heavily pretreated ER+ breast cancer PDX models.
Selective EP300 degrader outperformed clinical benchmark inobrodib in multiple myeloma models, including pomalidomide-resistant xenografts.
Cereblon-based selective ARID1B degraders achieved robust degradation with potential for oral bioavailability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.